HomeBUSINESS
BUSINESS

Maviret Sweeping Japan Hep C Market, 80% Share Snatched in Just 4 Months?
(Jun.22.2018)

The power map of the Japanese hepatitis C market has been changing rapidly. Since the emergence of interferon (INF)-free direct-acting antiviral agents (DAAs), drug makers have raced to roll out a series of DAA products, and now the last entrant, Maviret (glecaprevir + pibrentasvir), appears to be enjoying a big chunk of that market thanks to its short treatment period and pan-genotype feature ...
(LOG IN FOR FULL STORY)